KYORIN Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis
KYORIN Pharmaceutical Co., Ltd. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Mature dividend-paying pharma company with declining earnings facing restructuring pressures in competitive generic and specialty drug markets. KYORIN operates as an established Japanese pharmaceutical player with a diverse product portfolio and dividend history. However, earnings per share has fallen approximately 8.9% per year over the past five years.
What is KYORIN Pharmaceutical Co., Ltd.'s industry? KYORIN Pharmaceutical Co., Ltd. (kyorin-pharm.co.jp) operates in Pharmaceuticals & Biotech. AskCyborg classifies KYORIN Pharmaceutical Co., Ltd. under Pharmaceuticals & Biotech in its company registry.
KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and...
Cyborg Score thesis
Mature dividend-paying pharma company with declining earnings facing restructuring pressures in competitive generic and specialty...
Read the full analyst-debate transcript →Get the Latest KYORIN Pharmaceutical Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeKYORIN Pharmaceutical Co., Ltd. Overview
Pro stress-test →KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and other products. Through its subsidiaries, the company researches, develops, manufactures, and sells ethical and generic drugs in Japan and internationally.
Strategic Profile
Pro stress-test →The company offers a portfolio of specialty therapeutics including Flutiform (asthma), Pentasa (ulcerative colitis/Crohn's disease), and Nasonex (allergic rhinitis), alongside diagnostics and contract manufacturing services. KYORIN has development and commercialization agreements with innovators like Hyfe Inc. for digital therapeutics focused on chronic cough.
Competitive Landscape
Pro stress-test →KYORIN competes in Japan's fragmented pharmaceutical market against larger global players (Takeda, Daiichi Sankyo, Astellas) and generic manufacturers. The company's focus on specialty therapeutics and licensing partnerships provides differentiation, though scale disadvantages persist in competing for blockbuster drugs.
Industry Context
KYORIN Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Biotech.
Key facts
Founded: 1923 · Headquarters: Tokyo, Japan · Employees: 2,000 · Revenue: Not available in search results · Market cap: ¥88.53B (~$600M USD equivalent)